ClinicalTrials.gg
CompletedNCT02953548Updated Sep 2, 2022Results posted

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

A Phase 3 interventional study of GWP42003-P in Infantile Spasms, sponsored by Jazz Pharmaceuticals. Completed at 8 sites in 2 countries. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
1 Month to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Spasms, Infantile with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Spasms, Infantile · United States.

Enrollment
10th of 18
9 · median 10
Started
2017
with 1 other
Phase 3
7 of 22
none open now
Registered
9th of 22
by date
Lead sponsor
3 of 22
Jazz Pharmaceuticals

Among the 22 studies in Spasms, Infantile with a site in United States, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 9th registered.

Spasms, Infantile

47 studies on the registry are indexed under Spasms, Infantile; 8 are open to participants now.

Browse Spasms, Infantile studies →

Open to participants now

2 of the 22 studies in Spasms, Infantile with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Spasms, Infantile studies recruiting now, none set no upper age limit and 7 stop at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 1 Month to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Spasms, Infantile with a site in United States, or all of them as a file.
02

Study summary

This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The pilot phase only will be described in this record. 2 cohorts of 5 participants will be enrolled sequentially. All participants will receive GWP42003-P.

03

Conditions studied

  • Infantile Spasms

Browse trials for

Keywords

  • GWP42003-P
  • Cannabidiol
04

Who can participate

Ages eligible
1 Month to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant is aged 6- 24 months (inclusive) in the first cohort or aged 1-24 months (inclusive) in the second cohort, at the time of consent.
  • Participant is diagnosed with IS and has failed to respond adequately following treatment with 1 or more approved IS therapies.
  • To be considered hypsarrhythmia, as defined for use in the study, the electroencephalography (EEG) background must be slowed and have multifocal spikes. In addition, it must be either high voltage (above 300 µV) or have electrodecrement/discontinuity.

Key Exclusion Criteria:

  • Participant is currently taking or has taken clobazam or any mammalian target of rapamycin (mTOR) inhibitor within the 2 weeks prior to the screening visit.
  • Participant has a , corrected for heart rate with Bazett's formula (QTcB), of 460 msec or greater on .
  • Participant's caregiver is currently giving or has given recreational or medicinal cannabis, or synthetic cannabinoid-based medications, within the 1 month prior to the screening visit.
  • Participant's caregiver is unwilling to abstain from giving the participant (including the participant's mother abstaining themselves, if breastfeeding)recreational or medicinal cannabis, or synthetic cannabinoid-based medications (other than the study drug) during the trial.
  • Participant has any known or suspected to cannabinoids or any of the of the study drug, such as sesame oil.
  • Participant has significantly impaired hepatic function at the screening visit.
  • Participant has received an medicinal product as part of a clinical trial within a minimum of 5 half-lives prior to the screening visit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    GWP42003-P

    Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.

    Drug: GWP42003-P

Interventions

  • Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

    Also known as: CBD, Cannabidiol

06

What researchers measure

Primary outcomes

  1. Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)

    TEAEs are defined as all adverse events not present prior to the first investigational medicinal product (IMP) or placebo administration or any event already present that worsened in severity or frequency following IMP.

    Time frame: From signing of informed consent up to Day 15

  2. Number of Participants With Any Low or High Hematology Laboratory Parameter Value

    Time frame: Day 4 and Day 15

  3. Number of Participants With Any Low or High Biochemistry Laboratory Parameter Value

    Time frame: Day 4 and Day 15

  4. Number of Participant With Any Clinically Relevant Urinalysis Parameter Value

    Clinical relevance was determined by the investigator.

    Time frame: Day 4 and Day 15

  5. Number of Participants With Clinically Significant Electrocardiogram Findings

    Clinical significance was determined by the investigator.

    Time frame: From signing of informed consent up to Day 15

  6. Number of Participants With Clinically Significant Physical Examination Findings

    Clinical significance was determined by the investigator.

    Time frame: From signing of informed consent up to Day 15

  7. Number of Participants With Clinically Significant Vital Sign Findings

    Clinical significance was determined by the investigator.

    Time frame: From signing of informed consent up to Day 15

Secondary outcomes

  1. Number of Participants Free of Clinical Spasms

    Clinical spasms were determined by video-electroencephalography (VEEG) for at least 8 hours and up to 24 hours.

    Time frame: Day 15

  2. Percentage of Participants Free of Clinical Spasms

    Clinical spasms were determined by VEEG for at least 8 hours and up to 24 hours.

    Time frame: Day 15

  3. Number of Participants With Resolution of Hypsarrhythmia

    Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.

    Time frame: Day 15

  4. Percentage of Participants With Resolution of Hypsarrhythmia

    Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.

    Time frame: Day 15

  5. Number of Participants Experiencing Spasms and Seizures by Subtype

    Caregivers recorded the participant's spasms and seizures by category in a daily diary. Subtypes of spasms and seizures included: clonic, tonic-clonic, myoclonic, focal, and absence.

    Time frame: Day 4 and Day 15

  6. Average Time to Cessation of Spasms

    Analysis could not be conducted for this outcome measure because the study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment and demonstrated continued hypsarrhythmia and spasms on follow-up VEEG. The Pivotal Phase was not initiated; however, participants completing the Pilot Phase could roll into the Open Label Extension Phase (NCT02954887) for up to 1 year.

    Time frame: Day 1 to start of Open-label Extension (OLE) Phase

  7. Caregiver Clinical Global Impression of Change (CGIC)

    The CGIC is a single-question assessment completed by the caregiver. The question assessed the status of the participant's condition since treatment start. The caregiver provided a rating on a 7-point scale from 1 (very much improved) to 7 (very much worse).

    Time frame: Day 15

  8. Physician Global Impression of Change (PGIC)

    The PGIC is a single-question assessment completed by the investigator. The question assesses the status of the participant's condition since treatment start. The investigator provided a rating on a 7-point scale from 1 (very much improved) to 7 (very much worse).

    Time frame: Day 15

  9. Number of Responders

    A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Testing for responders was conducted by VEEG for at least 8 hours and up to 24 hours.

    Time frame: Baseline to Day 15

  10. Percentage of Responders

    A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Testing for responders was conducted by VEEG for at least 8 hours and up to 24 hours.

    Time frame: Baseline to Day 15

07

Results

Posted Jul 23, 2020
Limitations and caveats
This study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment, and the Pivotal Phase was not initiated. Participants completing the Pilot Phase could roll into the Open Label Extension Phase for up to 1 year.

Participant flow

Participants were screened to assess their eligibility to enter the trial within 7 days prior to the first dose administration.

Participant flow — Overall Study
MilestoneCohort 1: GWP42003-P OSCohort 2: GWP42003-P OS
Started54
Completed54
Not completed00

Outcome measures

PrimaryNumber of Participants With Severe Treatment-emergent Adverse Events (TEAEs)

TEAEs are defined as all adverse events not present prior to the first investigational medicinal product (IMP) or placebo administration or any event already present that worsened in severity or frequency following IMP.

Time frame:
From signing of informed consent up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)
ParticipantsGWP42003-P OS
Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)6
PrimaryNumber of Participants With Any Low or High Hematology Laboratory Parameter Value
Time frame:
Day 4 and Day 15
Reported as:
Count of participants · Participants
Number of Participants With Any Low or High Hematology Laboratory Parameter Value
ParticipantsGWP42003-P OS
Day 4, Low4
Day 4, High4
Day 15, Low1
Day 15, High3
PrimaryNumber of Participants With Any Low or High Biochemistry Laboratory Parameter Value
Time frame:
Day 4 and Day 15
Reported as:
Count of participants · Participants
Number of Participants With Any Low or High Biochemistry Laboratory Parameter Value
ParticipantsGWP42003-P OS
Day 4, Low7
Day 4, High5
Day 15, Low5
Day 15, High7
PrimaryNumber of Participant With Any Clinically Relevant Urinalysis Parameter Value

Clinical relevance was determined by the investigator.

Time frame:
Day 4 and Day 15
Reported as:
Count of participants · Participants
Number of Participant With Any Clinically Relevant Urinalysis Parameter Value
ParticipantsGWP42003-P OS
Day 40
Day 150
PrimaryNumber of Participants With Clinically Significant Electrocardiogram Findings

Clinical significance was determined by the investigator.

Time frame:
From signing of informed consent up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram Findings
ParticipantsGWP42003-P OS
Number of Participants With Clinically Significant Electrocardiogram Findings0
PrimaryNumber of Participants With Clinically Significant Physical Examination Findings

Clinical significance was determined by the investigator.

Time frame:
From signing of informed consent up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Physical Examination Findings
ParticipantsGWP42003-P OS
Number of Participants With Clinically Significant Physical Examination Findings0
PrimaryNumber of Participants With Clinically Significant Vital Sign Findings

Clinical significance was determined by the investigator.

Time frame:
From signing of informed consent up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Findings
ParticipantsGWP42003-P OS
Number of Participants With Clinically Significant Vital Sign Findings0
SecondaryNumber of Participants Free of Clinical Spasms

Clinical spasms were determined by video-electroencephalography (VEEG) for at least 8 hours and up to 24 hours.

Time frame:
Day 15
Reported as:
Count of participants · Participants
Number of Participants Free of Clinical Spasms
ParticipantsGWP42003-P OS
Number of Participants Free of Clinical Spasms0
SecondaryPercentage of Participants Free of Clinical Spasms

Clinical spasms were determined by VEEG for at least 8 hours and up to 24 hours.

Time frame:
Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Free of Clinical Spasms
percentage of participantsGWP42003-P OS
Percentage of Participants Free of Clinical Spasms0
SecondaryNumber of Participants With Resolution of Hypsarrhythmia

Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.

Time frame:
Day 15
Reported as:
Count of participants · Participants
Number of Participants With Resolution of Hypsarrhythmia
ParticipantsGWP42003-P OS
Number of Participants With Resolution of Hypsarrhythmia0
SecondaryPercentage of Participants With Resolution of Hypsarrhythmia

Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.

Time frame:
Day 15
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Hypsarrhythmia
percentage of participantsGWP42003-P OS
Percentage of Participants With Resolution of Hypsarrhythmia0
SecondaryNumber of Participants Experiencing Spasms and Seizures by Subtype

Caregivers recorded the participant's spasms and seizures by category in a daily diary. Subtypes of spasms and seizures included: clonic, tonic-clonic, myoclonic, focal, and absence.

Time frame:
Day 4 and Day 15
Reported as:
Count of participants · Participants
Number of Participants Experiencing Spasms and Seizures by Subtype
ParticipantsGWP42003-P OS
Day 4, Clonic0
Day 4, Tonic-Clonic1
Day 4, Atonic0
Day 4, Myoclonic0
Day 4, Focal1
Day 4, Absence0
Day 4, Not Done0
Day 15, Clonic0
Day 15, Tonic-Clonic0
Day 15, Atonic0
Day 15, Myoclonic0
Day 15, Focal2
Day 15, Absence0
Day 15, Not Done0
SecondaryAverage Time to Cessation of Spasms

Analysis could not be conducted for this outcome measure because the study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment and demonstrated continued hypsarrhythmia and spasms on follow-up VEEG. The Pivotal Phase was not initiated; however, participants completing the Pilot Phase could roll into the Open Label Extension Phase (NCT02954887) for up to 1 year.

Time frame:
Day 1 to start of Open-label Extension (OLE) Phase

No measurements were reported for this outcome.

SecondaryCaregiver Clinical Global Impression of Change (CGIC)

The CGIC is a single-question assessment completed by the caregiver. The question assessed the status of the participant's condition since treatment start. The caregiver provided a rating on a 7-point scale from 1 (very much improved) to 7 (very much worse).

Time frame:
Day 15
Reported as:
Number · participants
Caregiver Clinical Global Impression of Change (CGIC)
participantsGWP42003-P OS
Very Much Improved1
Much Improved0
Slightly Improved7
No Change1
Slightly Worse0
Much Worse0
Very Much Worse0
Not Done0
SecondaryPhysician Global Impression of Change (PGIC)

The PGIC is a single-question assessment completed by the investigator. The question assesses the status of the participant's condition since treatment start. The investigator provided a rating on a 7-point scale from 1 (very much improved) to 7 (very much worse).

Time frame:
Day 15
Reported as:
Number · participants
Physician Global Impression of Change (PGIC)
participantsGWP42003-P OS
Very Much Improved0
Much Improved1
Slightly Improved5
No Change3
Slightly Worse0
Much Worse0
Very Much Worse0
Not Done0
SecondaryNumber of Responders

A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Testing for responders was conducted by VEEG for at least 8 hours and up to 24 hours.

Time frame:
Baseline to Day 15
Reported as:
Number · responders
Number of Responders
respondersCohort 1: GWP42003-P OSCohort 2: GWP42003-P OS
Number of Responders00
SecondaryPercentage of Responders

A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Testing for responders was conducted by VEEG for at least 8 hours and up to 24 hours.

Time frame:
Baseline to Day 15
Reported as:
Number · responders
Percentage of Responders
respondersCohort 1: GWP42003-P OSCohort 2: GWP42003-P OS
Percentage of Responders00

Adverse events

Collected over From signing of informed consent up to Day 15. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P OS0/9 (0%)1/9 (11.1%)5/9 (55.6%)
Most frequent serious events
Most frequent serious events
EventGWP42003-P OS
Status epilepticusNervous system disorders1/9
Most frequent other events
Most frequent other events
EventGWP42003-P OS
DiarrhoeaGastrointestinal disorders2/9
Upper respiratory tract infectionInfections and infestations2/9
Application site erosionGeneral disorders1/9
IrritabilityPsychiatric disorders1/9
CoughRespiratory, thoracic and mediastinal disorders1/9
SomnolenceNervous system disorders1/9
ConstipationGastrointestinal disorders1/9
VomitingGastrointestinal disorders1/9
HaematuriaRenal and urinary disorders1/9
Increased appetiteMetabolism and nutrition disorders1/9

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(years)GWP42003-P OS
Mean12.2 ± 5.56
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P OS
Female6
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GWP42003-P OS
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race0
Unknown or Not Reported1
08

Study locations

8 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • The Childrens Hospital of San Antonio
    San Antonio, Texas 78207, United States
  • Valley Health Clinical Research
    Winchester, Virginia 22601, United States
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, Poland
  • Centrum Medyczne POMOC
    Łódź, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in May 2018, 12 months.

Results were first posted in Jul 2020, 2 years 2 months after primary completion. A results delay was requested in Dec 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2016
First posted
Nov 2, 2016
StartActual
Apr 24, 2017
Primary completionActual
May 7, 2018
CompletionActual
May 7, 2018
Results delay requested
Dec 12, 2019
Results first posted
Jul 23, 2020
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02953548
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
Apr 24, 2017
Primary completion
May 7, 2018
Completion
May 7, 2018
Results posted
Jul 23, 2020
Last update
Sep 2, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion